CN116082694A - 一种用于组织创面修复的海绵复合物及其制备方法 - Google Patents
一种用于组织创面修复的海绵复合物及其制备方法 Download PDFInfo
- Publication number
- CN116082694A CN116082694A CN202210713997.XA CN202210713997A CN116082694A CN 116082694 A CN116082694 A CN 116082694A CN 202210713997 A CN202210713997 A CN 202210713997A CN 116082694 A CN116082694 A CN 116082694A
- Authority
- CN
- China
- Prior art keywords
- sponge
- deionized water
- oxidized
- sodium alginate
- dopamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 150000001875 compounds Chemical class 0.000 title claims abstract description 20
- 230000037314 wound repair Effects 0.000 title claims abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 53
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims abstract description 48
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims abstract description 27
- 229920002307 Dextran Polymers 0.000 claims abstract description 27
- 239000000661 sodium alginate Substances 0.000 claims abstract description 27
- 235000010413 sodium alginate Nutrition 0.000 claims abstract description 27
- 229940005550 sodium alginate Drugs 0.000 claims abstract description 27
- 229960003638 dopamine Drugs 0.000 claims abstract description 24
- 239000002131 composite material Substances 0.000 claims abstract description 23
- 229920001503 Glucan Polymers 0.000 claims abstract description 3
- 239000008367 deionised water Substances 0.000 claims description 40
- 229910021641 deionized water Inorganic materials 0.000 claims description 40
- 239000003795 chemical substances by application Substances 0.000 claims description 28
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 claims description 20
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 12
- 238000000502 dialysis Methods 0.000 claims description 12
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 10
- 238000005303 weighing Methods 0.000 claims description 10
- NQXWGWZJXJUMQB-UHFFFAOYSA-K iron trichloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].Cl[Fe+]Cl NQXWGWZJXJUMQB-UHFFFAOYSA-K 0.000 claims description 9
- 238000004108 freeze drying Methods 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 230000001105 regulatory effect Effects 0.000 claims description 6
- 229910001961 silver nitrate Inorganic materials 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 239000007777 multifunctional material Substances 0.000 claims description 3
- 230000029663 wound healing Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 12
- 239000000463 material Substances 0.000 abstract description 9
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 abstract description 6
- 238000010521 absorption reaction Methods 0.000 abstract description 5
- 229910052742 iron Inorganic materials 0.000 abstract description 4
- 230000004663 cell proliferation Effects 0.000 abstract description 3
- 238000002474 experimental method Methods 0.000 abstract description 3
- 238000000338 in vitro Methods 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 239000002262 Schiff base Substances 0.000 abstract description 2
- 150000004753 Schiff bases Chemical class 0.000 abstract description 2
- 230000015556 catabolic process Effects 0.000 abstract description 2
- 238000010382 chemical cross-linking Methods 0.000 abstract description 2
- 230000000536 complexating effect Effects 0.000 abstract description 2
- 239000003431 cross linking reagent Substances 0.000 abstract description 2
- 238000006731 degradation reaction Methods 0.000 abstract description 2
- -1 iron ions Chemical class 0.000 abstract description 2
- 239000011159 matrix material Substances 0.000 abstract description 2
- 239000012567 medical material Substances 0.000 abstract description 2
- 230000002503 metabolic effect Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 6
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 238000010668 complexation reaction Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- OAVCWZUKQIEFGG-UHFFFAOYSA-O 2-(5-methyl-2H-tetrazol-1-ium-1-yl)-1,3-thiazole Chemical compound CC1=NN=N[NH+]1C1=NC=CS1 OAVCWZUKQIEFGG-UHFFFAOYSA-O 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 239000010413 mother solution Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001878 scanning electron micrograph Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J9/00—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof
- C08J9/28—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof by elimination of a liquid phase from a macromolecular composition or article, e.g. drying of coagulum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/18—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/20—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing organic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/425—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/64—Use of materials characterised by their function or physical properties specially adapted to be resorbable inside the body
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0084—Guluromannuronans, e.g. alginic acid, i.e. D-mannuronic acid and D-guluronic acid units linked with alternating alpha- and beta-1,4-glycosidic bonds; Derivatives thereof, e.g. alginates
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J9/00—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof
- C08J9/0061—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof characterized by the use of several polymeric components
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J9/00—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof
- C08J9/0066—Use of inorganic compounding ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2201/00—Foams characterised by the foaming process
- C08J2201/04—Foams characterised by the foaming process characterised by the elimination of a liquid or solid component, e.g. precipitation, leaching out, evaporation
- C08J2201/048—Elimination of a frozen liquid phase
- C08J2201/0484—Elimination of a frozen liquid phase the liquid phase being aqueous
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2207/00—Foams characterised by their intended use
- C08J2207/10—Medical applications, e.g. biocompatible scaffolds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2305/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00
- C08J2305/02—Dextran; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2305/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00
- C08J2305/04—Alginic acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2405/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2401/00 or C08J2403/00
- C08J2405/02—Dextran; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2405/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2401/00 or C08J2403/00
- C08J2405/04—Alginic acid; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Materials For Medical Uses (AREA)
Abstract
本发明涉及医药材料技术领域，具体涉及基于一种用于组织创面修复的海绵复合物及其制备方法。本发明海绵复合物通过络合铁离子后，复合材料远比单独的葡聚糖海绵有更强抗菌活性；海绵复合物具有强吸水性。本发明将氧化葡聚糖和氧化海藻酸钠分别和多巴胺通过希夫碱连接，明显增加了复合海绵的吸水性和回弹性；本发明海绵复合物制备材料中未采用任何化学交联剂，材料基质均可由人体代谢吸收，代谢降解速率快，体外细胞实验表明该海绵复合物有促进细胞增值的功能。
Description
技术领域
本发明涉及医药材料技术领域，具体涉及基于一种用于组织创面修复的海绵复合物及其制备方法。
背景技术
由病菌引起的伤口感染是目前治疗创面并促进其愈合所面临的一项挑战。因此，应用于伤口愈合的多功能材料具有抗菌活性是一项优势。如今市售的海绵仅适用于普通伤口，几乎没有抑菌效果。对于出血过多，有细菌感染的潜在可能的伤口，市售海绵并不能完全满足需求。
发明内容
一方面，本发明提供了一种用于组织创面修复的海绵复合物的制备方法，其包括以下步骤：
1)氧化海藻酸钠的制备：分别称取海藻酸钠和高碘酸钠溶于去离子水中，室温下以500rpm的转速搅拌24小时，随后转移到截留分子量为14000的透析袋，在去离子水中透析60h，滴加硝酸银到去离子水中，若无絮状物产生则为透析完全，随即冻干得氧化海藻酸钠AS；
2)氧化葡聚糖的制备：分别称取葡聚糖和高碘酸钠溶于去离子水中，室温下以500rpm的转速搅拌24小时，随后转移到截留分子量为14000的透析袋，在去离子水中透析60h，滴加硝酸银到去离子水中，若无絮状物产生则为透析完全，随即冻干得氧化葡聚糖AG；
3)氧化海藻酸钠接枝多巴胺的制备：称取步骤1)中制备的氧化海藻酸钠，溶于去离子水，PH调至7.0，随后加入多巴胺，在氮气保护下反应5h，转至截留分子量为14000的透析袋，透析48h，冻干得到目标产物氧化海藻酸钠接枝多巴胺AS/DA；
4)氧化葡聚糖接枝多巴胺的制备：称取上述步骤2)中制备的氧化葡聚糖，溶于去离子水，PH调至7.0，随后加入多巴胺，在氮气保护下反应5h，转至截留分子量为14000的透析袋，透析48h，冻干得到目标产物氧化葡聚糖接枝多巴胺AG/DA；
5)海绵复合物的制备：取AG/DA和AS/DA于去离子水中(热水浴溶解)，加六水合三氯化铁，在室温下以200rpm转速搅拌12h，后转移至模具中，静置4h，然后冷冻干燥，得海绵复合物。
在一些实施方式中，所述步骤1)中海藻酸钠与高碘酸钠的重量比为1：1.5。
在一些实施方式中，所述步骤1)中海藻酸钠与去离子水的重量体积比g/ml为1：20。
在一些实施方式中，所述步骤2)中葡聚糖与高碘酸钠的重量比为1：1.5。
在一些实施方式中，所述步骤2)中葡聚糖与去离子水的重量体积比g/ml为1：20。
在一些实施方式中，所述步骤3)中氧化海藻酸钠与多巴胺的重量比为1:1。
在一些实施方式中，所述步骤3)中氧化海藻酸钠与去离子水的重量体积比g:ml为3:80。
在一些实施方式中，所述步骤4)中氧化葡聚糖与多巴胺的重量比为1:1。
在一些实施方式中，所述步骤4)中氧化葡聚糖与去离子水的重量体积比g:ml为3:80。
在一些实施方式中，所述步骤5)中AG/DA与AS/DA的重量比为1:1～4:1。
在一些实施方式中，所述步骤5)中AG/DA与六水合三氯化铁的重量比为1:1～2:1。
另一方面，本发明提供了一种有上述制备方法制备得到的海绵复合物，该复合物有强抗菌活性，强吸水性，有促进细胞增值的功能。
再一方面，本发明提供所述海绵复合物在伤口愈合的多功能材料中的应用。
与现有技术相比，本发明海绵复合物通过络合铁离子后，复合材料远比单独的葡聚糖海绵有更强抗菌活性；海绵复合物具有强吸水性。本发明将氧化葡聚糖和氧化海藻酸钠分别和多巴胺通过希夫碱连接，明显增加了复合海绵的吸水性和回弹性；本发明海绵复合物制备材料中未采用任何化学交联剂，材料基质均可由人体代谢吸收，代谢降解速率快，体外细胞实验表明该海绵复合物有促进细胞增值的功能。
附图说明
图1为AS/DA,AG/DA，络合后AG/DA:AS/DA海绵复合物的形态图。
其中，a为AS/DA,b为AG/DA，c为通过铁络合后AG/DA:AS/DA变成块状海绵复合物。
图2为不同比例的海绵复合物的SEM图。
图3为不同比例的海绵复合物抗菌性能测试图。
图4为不同海绵复合物对L929的细胞毒性作用。
具体实施方式
下列实施例用于进一步解释说明本发明，但是，它们并不构成对本发明范围的限制或限定。
实施例1氧化海藻酸钠或氧化葡聚糖接多巴胺的制备及表征
AG：氧化葡聚糖DA：多巴胺AS：氧化海藻酸钠
制备氧化海藻酸：分别称取5g海藻酸钠和7.5g高碘酸钠溶于100ml去离子水中，室温下以500rpm的转速搅拌24小时，随后转移到截留分子量为14000的透析袋，在去离子水中透析60h，滴加硝酸银到去离子水中，若无絮状物产生则为透析完全，随即冻干得AS。
制备氧化葡聚糖：分别称取5g葡聚糖和7.5g高碘酸钠溶于100ml去离子水中，室温下以500rpm的转速搅拌24小时，随后转移到截留分子量为14000的透析袋，在去离子水中透析60h，滴加硝酸银到去离子水中，若无絮状物产生则为透析完全，随即冻干得AG。
氧化海藻酸钠接枝多巴胺：称取上述制备的氧化海藻酸钠3g，溶于80ml的去离子水(HCl调至7.0)，随后加入3g的多巴胺，在氮气保护下反应5h，转至截留分子量为14000的透析袋，透析48h，冻干得到目标产物AS/DA。
氧化葡聚糖接枝多巴胺：称取上述制备的氧化葡聚糖3g，溶于80ml的去离子水(HCl调至7.0)，随后加入3g的多巴胺，在氮气保护下反应5h，转至截留分子量为14000的透析袋，透析48h，冻干得到目标产物AG/DA。
如图1所示，AS/DA为黄色片状物，AG/DA为黄色粉末，将两者通过铁络合后AG/DA:AS/DA变成块状海绵复合物。
实施例2制备不同比例的海绵复合物
纯AG/DA：取0.9g AG到16ml去离子水中(热水浴溶解)，加0.45g六水合三氯化铁，在室温下以200rpm转速搅拌12h，后转移至1cm*1cm*1cm模具中，静置4h，然后冷冻干燥，该比例的海绵复合物命名为C0。
AG/DA:AS/DA＝1:1：取0.45g AG/DA和0.45g AS/DA，到16ml去离子水中(热水浴溶解)，加0.45g六水合三氯化铁，在室温下以200rpm转速搅拌12h，后转移至1cm*1cm*1cm模具中，静置4h，然后冷冻干燥，该比例的海绵复合物命名为C1。
AG/DA:AS/DA＝2:1：取0.6g AG/DA和0.3g AS/DA，到16ml去离子水中(热水浴溶解)，加0.45g六水合三氯化铁，在室温下以200rpm转速搅拌12h，后转移至1cm*1cm*1cm模具中，静置4h，然后冷冻干燥，该比例的海绵复合物命名为C2。
AG/DA:AS/DA＝3:1：取0.675g AG/DA和0.225g AS/DA，到16ml去离子水中(热水浴溶解)，加0.45g六水合三氯化铁，在室温下以200rpm转速搅拌12h，后转移至1cm*1cm*1cm模具中，静置4h，然后冷冻干燥，该比例的海绵复合物命名为C3。
AG/DA:AS/DA＝4:1：取0.72g AG/DA和0.18g AS/DA，到16ml去离子水中(热水浴溶解)，加0.45g六水合三氯化铁，在室温下以200rpm转速搅拌12h，后转移至1cm*1cm*1cm模具中，静置4h，然后冷冻干燥，该比例的海绵复合物命名为C4。
扫描电子显微镜(SEM)表征方法：取适量样品于导电胶上，并置于样品台，喷金处理，使用扫描电子显微镜在3.0kv加速电压下观察微球表面形貌，见图2。
实施例3不同比例的海绵复合物的抗菌性能测试
对以上5种比例的海绵复合物进行抗菌预实验，用铜绿假单胞菌(革兰氏阴性菌)考察了其抗菌性能。
抗菌试验：将铜绿假单胞菌的单菌落置于10mL胰蛋白胨大豆肉汤培养基(TSB)中培养12h。采用麦氏比浊法测量细菌悬浮液得浓度，然后使用无菌水逐步稀释细菌浓度至108CFU/mL。用打孔器将1*1*1cm的海绵复合物进行打孔，得到直径为0.8cm得圆柱状材料，加入到培养皿中已挖空的中心(直径为0.9cm)，再滴加适量的去离子水。将培养皿放置37℃下培养12h。结果如图3所示：不同比例的海绵复合物抗菌性能优异，C1和C4的抗菌效果较好。
实施例4不同比例的海绵复合物的体外生物相容性研究
研究了不同比例的海绵复合物对小鼠成纤维细胞(L929)的毒性作用：采用3-(4,5-二甲基噻唑-2)-2,5-二苯基四氮唑溴盐(MTT)法测定细胞毒性。通过培养的小鼠成纤维细胞(L-929)评价材料的细胞毒性。L-929细胞株于低糖培养基(MEM)中培育：含10％的胎牛血清，500μg/m L的青霉素和100μg/mL的链霉素。细胞在5％的二氧化碳的37℃培养箱中培养。首先将L-929均匀接种于96孔板中，密度为5×106个/板，二氧化碳培养箱中培养12h，使细胞均匀铺满孔板底部，每孔含有180μL的培养液。将材料用研钵研碎后称量，然后细胞房传递窗紫外照射半小时。灭菌后浸入MEM完全培养基中(37℃)培养24h，母液浓度为5mg/mL，逐步稀释得到不同浓度的材料，取20μL各种浓度的材料加入每孔中，使药物作用浓度为5μg/mL～100μg/mL，空白组为加入20μL培养基进行对比，96孔板培养24h后，每孔加入20μL的5mg/mL的MTT(避光操作)，继续培养4h，移除上层悬浮液，每孔再加入150μL二甲基亚砜(DMSO)，水平振荡10min后用酶标仪测定490nm处的OD值。其中ODtest为药物处理后细胞孔的吸光度值，ODcontrol为空白对照孔的吸光度值相对细胞活力计算：
结果见图4：不同比例的海绵复合物均无明显的细胞毒性，具有良好的生物相容性。
以上所述，仅为本发明较佳的具体实施方式，但本发明的保护范围并不局限于此，任何熟悉本技术领域的技术人员在本发明披露的技术范围内，根据本发明的技术方案及其发明构思加以等同替换或改变，都应涵盖在本发明的保护范围之内。
Claims (9)
1.一种用于组织创面修复的海绵复合物的制备方法，其特征在于包括以下步骤：
1)氧化海藻酸钠的制备：分别称取海藻酸钠和高碘酸钠溶于去离子水中，室温下以500rpm的转速搅拌24小时，随后转移到截留分子量为14000的透析袋，在去离子水中透析60h，滴加硝酸银到去离子水中，若无絮状物产生则为透析完全，随即冻干得氧化海藻酸钠AS；
2)氧化葡聚糖的制备：分别称取葡聚糖和高碘酸钠溶于去离子水中，室温下以500rpm的转速搅拌24小时，随后转移到截留分子量为14000的透析袋，在去离子水中透析60h，滴加硝酸银到去离子水中，若无絮状物产生则为透析完全，随即冻干得氧化葡聚糖AG；
3)氧化海藻酸钠接枝多巴胺的制备：称取步骤1)中制备的氧化海藻酸钠，溶于去离子水，PH调至7.0，随后加入多巴胺，在氮气保护下反应5h，转至截留分子量为14000的透析袋，透析48h，冻干得到目标产物氧化海藻酸钠接枝多巴胺AS/DA；
4)氧化葡聚糖接枝多巴胺的制备：称取上述步骤2)中制备的氧化葡聚糖，溶于去离子水，PH调至7.0，随后加入多巴胺，在氮气保护下反应5h，转至截留分子量为14000的透析袋，透析48h，冻干得到目标产物氧化葡聚糖接枝多巴胺AG/DA；
5)海绵复合物的制备：取AG/DA和AS/DA于去离子水中(热水浴溶解)，加六水合三氯化铁，在室温下以200rpm转速搅拌12h，后转移至模具中，静置4h，然后冷冻干燥，得海绵复合物。
2.如权利要求1所述一种用于组织创面修复的海绵复合物的制备方法，其特征在于所述步骤1)中海藻酸钠与高碘酸钠的重量比为1:1.5；步骤1)中海藻酸钠与去离子水的重量体积比g/ml为1:20。
3.如权利要求1所述一种用于组织创面修复的海绵复合物的制备方法，其特征在于所述步骤2)中葡聚糖与高碘酸钠的重量比为1:1.5；所述步骤2)中葡聚糖与去离子水的重量体积比g/ml为1:20。
4.如权利要求1所述一种用于组织创面修复的海绵复合物的制备方法，其特征在于所述步骤3)中氧化海藻酸钠与多巴胺的重量比为1:1；所述步骤3)中氧化海藻酸钠与去离子水的重量体积比g:ml为3:80。
5.如权利要求1所述一种用于组织创面修复的海绵复合物的制备方法，其特征在于所述步骤4)中氧化葡聚糖与多巴胺的重量比为1:1；所述步骤4)中氧化葡聚糖与去离子水的重量体积比g:ml为3:80。
6.如权利要求1所述一种用于组织创面修复的海绵复合物的制备方法，其特征在于所述步骤5)中AG/DA与AS/DA的重量比为1:1～4:1。
7.如权利要求1所述一种用于组织创面修复的海绵复合物的制备方法，其特征在于所述步骤5)中AG/DA与六水合三氯化铁的重量比为1:1～2:1。
8.如权利要求1-7中任一项所述的制备方法制备得到的海绵复合物。
9.如权利要求8所述的海绵复合物在伤口愈合的多功能材料中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210713997.XA CN116082694B (zh) | 2022-06-22 | 2022-06-22 | 一种用于组织创面修复的海绵复合物及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210713997.XA CN116082694B (zh) | 2022-06-22 | 2022-06-22 | 一种用于组织创面修复的海绵复合物及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116082694A true CN116082694A (zh) | 2023-05-09 |
| CN116082694B CN116082694B (zh) | 2024-02-09 |
Family
ID=86210802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210713997.XA Active CN116082694B (zh) | 2022-06-22 | 2022-06-22 | 一种用于组织创面修复的海绵复合物及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116082694B (zh) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106589409A (zh) * | 2016-11-28 | 2017-04-26 | 上海大学 | 聚谷氨酸/海藻酸钠粘附性水凝胶及其制备方法 |
| CN106581734A (zh) * | 2016-11-22 | 2017-04-26 | 孙祎 | 一种高抗菌性藻酸盐敷料的制备方法 |
| CN109705369A (zh) * | 2018-12-27 | 2019-05-03 | 暨南大学 | 一种海藻酸钠-多巴胺/聚乙烯醇水凝胶及其制备方法与应用 |
| CN109908876A (zh) * | 2019-04-22 | 2019-06-21 | 盐城工学院 | 一种多糖纳米微晶掺杂的壳聚糖基仿生吸附凝胶的制备方法及应用 |
| CN111286045A (zh) * | 2020-03-11 | 2020-06-16 | 广东省医疗器械研究所 | 一种多酚类物质氢键增强水凝胶 |
| CN113512133A (zh) * | 2021-05-26 | 2021-10-19 | 江苏诺瓦立医疗用品有限公司 | 生物组织粘合剂的制备方法 |
| CN114230812A (zh) * | 2021-12-07 | 2022-03-25 | 广东省科学院健康医学研究所 | 一种功能性水凝胶及其制备方法和应用 |
-
2022
- 2022-06-22 CN CN202210713997.XA patent/CN116082694B/zh active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106581734A (zh) * | 2016-11-22 | 2017-04-26 | 孙祎 | 一种高抗菌性藻酸盐敷料的制备方法 |
| CN106589409A (zh) * | 2016-11-28 | 2017-04-26 | 上海大学 | 聚谷氨酸/海藻酸钠粘附性水凝胶及其制备方法 |
| CN109705369A (zh) * | 2018-12-27 | 2019-05-03 | 暨南大学 | 一种海藻酸钠-多巴胺/聚乙烯醇水凝胶及其制备方法与应用 |
| CN109908876A (zh) * | 2019-04-22 | 2019-06-21 | 盐城工学院 | 一种多糖纳米微晶掺杂的壳聚糖基仿生吸附凝胶的制备方法及应用 |
| CN111286045A (zh) * | 2020-03-11 | 2020-06-16 | 广东省医疗器械研究所 | 一种多酚类物质氢键增强水凝胶 |
| CN113512133A (zh) * | 2021-05-26 | 2021-10-19 | 江苏诺瓦立医疗用品有限公司 | 生物组织粘合剂的制备方法 |
| CN114230812A (zh) * | 2021-12-07 | 2022-03-25 | 广东省科学院健康医学研究所 | 一种功能性水凝胶及其制备方法和应用 |
Non-Patent Citations (3)
| Title |
|---|
| JIE YANG: "Double Cross-Linked Chitosan Composite Films Developed with Oxidized Tannic Acid and Ferric Ions Exhibit High Strength and Excellent Water Resistance", 《BIO MACROMOLECULES》, vol. 20, pages 801 - 812 * |
| 姜月霞;张彦军;陈年根;李永纲;: "DOPA-壳聚糖止血海绵的基本特性及安全性评价", 齐齐哈尔医学院学报, no. 16 * |
| 李洁;许楗桢;胡萍;雷琪琪;张文柠;敖宁建;: "羧甲基壳聚糖/氧化魔芋葡甘聚糖复合海绵的制备与性能评价", 化学与生物工程, no. 08 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116082694B (zh) | 2024-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110117369B (zh) | 一种抗菌粘附的导电水凝胶及其制备方法和应用 | |
| CN110314242B (zh) | 一种可控释放的抗生素复合水凝胶的制备方法及其用途 | |
| CN102675651B (zh) | 抗菌敷料用壳聚糖水凝胶的制备方法 | |
| CN110152055B (zh) | 海藻酸胺化衍生物/细菌纤维素纳米晶复合凝胶构筑的功能性药物缓释医用敷料 | |
| Wu et al. | Long-term antibacterial composite via alginate aerogel sustained release of antibiotics and Cu used for bone tissue bacteria infection | |
| CN114392388A (zh) | 一种水凝胶组合物及其应用 | |
| CN112851951B (zh) | 一种接枝ε-聚赖氨酸的双醛基壳聚糖及其制备方法和应用 | |
| CN113773525B (zh) | 一种二硫化钼负载纳米银抗菌水凝胶的制备方法及其应用 | |
| CN112451738A (zh) | 一种银离子多糖聚合物抗菌敷料及其制备方法和应用 | |
| CN113663122B (zh) | 一种抗炎、抗菌、抗肿瘤的多功能水凝胶材料及其制备方法和应用 | |
| CN113813396B (zh) | 一种卡那霉素接枝的纤维素基抗菌材料及其制备方法 | |
| CN116082694B (zh) | 一种用于组织创面修复的海绵复合物及其制备方法 | |
| CN115850733B (zh) | 一种可注射用纳米粘土水凝胶及其制备方法和应用 | |
| CN114479124B (zh) | 一种可自愈水凝胶、其制备方法及应用 | |
| CN117159781A (zh) | 一种抗菌创面敷料及其制备方法 | |
| CN107441546B (zh) | 一种含银抗菌敷料的制备方法 | |
| CN112870431B (zh) | 具有g-四链体结构用作级联反应器的抗菌水凝胶及其制备方法及应用 | |
| CN113368037B (zh) | 一种载牛乳铁蛋白肽纳米粒壳聚糖温敏水凝胶及其制备方法和应用 | |
| CN115010958A (zh) | 一种用于促进伤口愈合的水凝胶及其制备方法和应用 | |
| CN116078175A (zh) | 一种基于壳聚糖的氮化碳-聚多巴胺-纳米银抗菌复合膜 | |
| CN112057667A (zh) | 一种可降解吸收的生物止血材料 | |
| CN115558128B (zh) | 一种具有过氧化物酶活性水凝胶敷料及其制备方法和应用 | |
| CN111234163A (zh) | 一种兼具抗菌修复性能的纳米凝胶及其制备方法与应用 | |
| Zvezdova | Applications of chitosan-sulfathiazole as antimicrobial agent | |
| CN114949338B (zh) | 一种可持久抗耐药菌水凝胶及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |